In the subgroup analysis, a benefit of mPFS was also observed in dual inhibition of LAG‐3 and PD‐1 over PD‐1 alone in BRAFmut melanoma, and the NRAS mutation status has not been revealed. Here, PDCD1 is linked to melanoma.